{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T03:44:44Z","timestamp":1787024684250,"version":"build-2736575974"},"reference-count":52,"publisher":"Bentham Science Publishers Ltd.","issue":"8","funder":[{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico","doi-asserted-by":"publisher","award":["303531\/2020-7"],"award-info":[{"award-number":["303531\/2020-7"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior","doi-asserted-by":"publisher","award":["88887.570091\/2020-00"],"award-info":[{"award-number":["88887.570091\/2020-00"]}],"id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior","doi-asserted-by":"publisher","award":["23038.006930\/2014\/59"],"award-info":[{"award-number":["23038.006930\/2014\/59"]}],"id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CN"],"published-print":{"date-parts":[[2022,8]]},"abstract":"<jats:sec>\n                    <jats:title>:<\/jats:title>\n                    <jats:p>Multiple sclerosis (MS) is a chronic neurodegenerative, inflammatory, and autoimmune\ndisease characterised by the demyelination of the central nervous system. One of the main approaches\nfor treating MS is the use of disease-modifying therapies (DMTs). Among the DMTs are\ninterferons (IFNs), which are cytokines responsible for controlling the activity of the immune system\nwhile exerting immunomodulatory, antiviral, and antiproliferative activities. IFN-beta (IFN-\u03b2)\nis the first-choice drug used to treat relapsing-remitting MS. However, the administration of IFN-\u03b2\ncauses numerous painful adverse effects, resulting in lower adherence to the treatment. Therefore,\nthis study aimed to investigate the headache and flu-like pain symptoms observed after IFN\u03b2 injection\nin MS patients using a systematic review and meta-analysis of randomised controlled trials. A\ntotal of 2370 articles were identified through research databases. Nine articles were included (three\ninvolving IFN\u03b2-1b and six involving IFN\u03b2-1a). All studies included in the meta-analysis had a low\nrisk of bias. The odds ratio of headache and flu-like pain symptoms increased in MS patients treated\nwith IFN-\u03b2. Thus, the adverse effects of headache and flu-like pain symptoms appear to be linked to\nIFN-\u03b2 treatment in MS. The protocol of the study was registered in the Prospective International\nRegistry of Systematic Reviews (registration number CRD42021227593).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2174\/1570159x19666211101142115","type":"journal-article","created":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T07:58:16Z","timestamp":1635753496000},"page":"1600-1612","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Interferon-Beta Injection in Multiple Sclerosis Patients Related to the Induction\nof Headache and Flu-Like Pain Symptoms: A Systematic Review\nand Meta-Analysis of Randomised Controlled Trials"],"prefix":"10.2174","volume":"20","author":[{"given":"Leonardo Gomes","family":"Pereira","sequence":"first","affiliation":[{"name":"Department of Physiology and Pharmacology, Graduated Program in Pharmacology, Federal University of Santa\nMaria (UFSM), 97105-900 Santa Maria (RS), Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patr\u00edcia","family":"Rodrigues","sequence":"additional","affiliation":[{"name":"Department of Physiology and Pharmacology, Graduated Program in Pharmacology, Federal University of Santa\nMaria (UFSM), 97105-900 Santa Maria (RS), Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernanda Tibolla","family":"Viero","sequence":"additional","affiliation":[{"name":"Department of Physiology and Pharmacology, Graduated Program in Pharmacology, Federal University of Santa\nMaria (UFSM), 97105-900 Santa Maria (RS), Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia Maria","family":"Frare","sequence":"additional","affiliation":[{"name":"Department of Physiology and Pharmacology, Graduated Program in Pharmacology, Federal University of Santa\nMaria (UFSM), 97105-900 Santa Maria (RS), Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu\u00eds Guilherme","family":"Ramanzini","sequence":"additional","affiliation":[{"name":"Department of Physiology and Pharmacology, Graduated Program in Pharmacology, Federal University of Santa\nMaria (UFSM), 97105-900 Santa Maria (RS), Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela","family":"Trevisan","sequence":"additional","affiliation":[{"name":"Department of Physiology and Pharmacology, Graduated Program in Pharmacology, Federal University of Santa\nMaria (UFSM), 97105-900 Santa Maria (RS), Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/ene.13819","volume":"26","author":"Dobson R.","year":"2019","unstructured":"Dobson R.; Giovannoni G.; Multiple sclerosis - a review. Eur J Neurol 2019,26(1),27-40","journal-title":"Eur J Neurol"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"269","DOI":"10.4103\/2319-4170.113187","volume":"36","author":"Ogura H.","year":"2013","unstructured":"Ogura H.; Arima Y.; Kamimura D.; Murakami M.; The gateway theory: how regional neural activation creates a gateway for immune cells via an inflammation amplifier. Biomed J 2013,36(6),269-273","journal-title":"Biomed J"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s13293-020-00326-3","volume":"11","author":"Voskuhl R.R.","year":"2020","unstructured":"Voskuhl R.R.; Patel K.; Paul F.; Gold S.M.; Scheel M.; Kuchling J.; Cooper G.; Asseyer S.; Chien C.; Brandt A.U.; Meyer C.E.; MacKenzie-Graham A.; Sex differences in brain atrophy in multiple sclerosis. Biol Sex Differ 2020,11(1),49","journal-title":"Biol Sex Differ"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1007\/s10072-017-3217-x","volume":"39","author":"Ferraro D.","year":"2018","unstructured":"Ferraro D.; Plantone D.; Morselli F.; Dallari G.; Simone A.M.; Vitetta F.; Sola P.; Primiano G.; Nociti V.; Pardini M.; Mirabella M.; Vollono C.; Systematic assessment and characterization of chronic pain in multiple sclerosis patients. Neurol Sci 2018,39(3),445-453","journal-title":"Neurol Sci"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"537","DOI":"10.2147\/JPR.S230680","volume":"13","author":"Elmazny A.","year":"2020","unstructured":"Elmazny A.; Hamdy S.M.; Abdel-Naseer M.; Shalaby N.M.; Shehata H.S.; Kishk N.A.; Nada M.A.; Mourad H.S.; Hegazy M.I.; Ab-delalim A.; Ahmed S.M.; Hatem G.; Fouad A.M.; Mahmoud H.; Hassan A.; Interferon-beta-induced headache in patients with multiple sclerosis: frequency and characterization. J Pain Res 2020,13(13),537-545","journal-title":"J Pain Res"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1159\/000382130","volume":"44","author":"Kalincik T.","year":"2015","unstructured":"Kalincik T.; Multiple sclerosis relapses: epidemiology, outcomes and management. A systematic review. Neuroepidemiology 2015,44(4),199-214","journal-title":"Neuroepidemiology"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1097\/WCO.0000000000000622","volume":"31","author":"Oh J.","year":"2018","unstructured":"Oh J.; Vidal-Jordana A.; Montalban X.; Multiple sclerosis: clinical aspects. Curr Opin Neurol 2018,31(6),752-759","journal-title":"Curr Opin Neurol"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"a028928","DOI":"10.1101\/cshperspect.a028928","volume":"8","author":"Klineova S.","year":"2018","unstructured":"Klineova S.; Lublin F.D.; Clinical course of multiple sclerosis. Cold Spring Harb Perspect Med 2018,8(9),a028928","journal-title":"Cold Spring Harb Perspect Med"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"fcaa185","DOI":"10.1093\/braincomms\/fcaa185","volume":"2","author":"Zeydan B.","year":"2020","unstructured":"Zeydan B.; Atkinson E.J.; Weis D.M.; Smith C.Y.; Gazzuola Rocca L.; Rocca W.A.; Keegan B.M.; Weinshenker B.G.; Kantarci K.; Kantarci O.H.; Reproductive history and progressive multiple sclerosis risk in women. Brain Commun 2020,2(2),fcaa185","journal-title":"Brain Commun"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1001\/jama.2020.26858","volume":"325","author":"McGinley M.P.","year":"2021","unstructured":"McGinley M.P.; Goldschmidt C.H.; Rae-Grant A.D.; Diagnosis and treatment of multiple sclerosis: a review. JAMA 2021,325(8),765-779","journal-title":"JAMA"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/S1474-4422(19)30485-5","volume":"19","author":"Chataway J.","year":"2020","unstructured":"Chataway J.; De Angelis F.; Connick P.; Parker R.A.; Plantone D.; Doshi A.; John N.; Stutters J.; MacManus D.; Prados Carrasco F.; Barkhof F.; Ourselin S.; Braisher M.; Ross M.; Cranswick G.; Pavitt S.H.; Giovannoni G.; Gandini Wheeler-Kingshott C.A.; Hawkins C.; Sharrack B.; Bastow R.; Weir C.J.; Stallard N.; Chandran S.; Efficacy of three neuroprotective drugs in secondary progressive multi-ple sclerosis (MS-SMART): a phase 2b, multiarm, double-blind, randomised placebo-controlled trial. Lancet Neurol 2020,19(3),214-225","journal-title":"Lancet Neurol"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1016\/S0140-6736(18)30481-1","volume":"391","author":"Thompson A.J.","year":"2018","unstructured":"Thompson A.J.; Baranzini S.E.; Geurts J.; Hemmer B.; Ciccarelli O.; Multiple sclerosis. Lancet 2018,391(10130),1622-1636","journal-title":"Lancet"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1016\/j.amjmed.2020.05.049","volume":"133","author":"Hauser S.L.","year":"2020","unstructured":"Hauser S.L.; Cree B.A.C.; Treatment of multiple sclerosis: a review. Am J Med 2020,133(12),1380-1390.e2","journal-title":"Am J Med"},{"key":"ref=14","first-page":"s159","volume":"22","author":"Hart F.M.","year":"2016","unstructured":"Hart F.M.; Bainbridge J.; Current and emerging treatment of multiple sclerosis. Am J Manag Care 2016,22(6)(Suppl.),s159-s170","journal-title":"Am J Manag Care"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1093\/brain\/aww258","volume":"140","author":"Correale J.","year":"2017","unstructured":"Correale J.; Gait\u00e1n M.I.; Ysrraelit M.C.; Fiol M.P.; Progressive multiple sclerosis: from pathogenic mechanisms to treatment. Brain 2017,140(3),527-546","journal-title":"Brain"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1177\/1756285611413825","volume":"4","author":"Limmroth V.","year":"2011","unstructured":"Limmroth V.; Putzki N.; Kachuck N.J.; The interferon beta therapies for treatment of relapsing-remitting multiple sclerosis: are they equally efficacious? A comparative review of open-label studies evaluating the efficacy, safety, or dosing of different interferon beta for-mulations alone or in combination. Ther Adv Neurol Disord 2011,4(5),281-296","journal-title":"Ther Adv Neurol Disord"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.1097\/01.wco.0000413319.87092.19","volume":"25","author":"Miller A.E.","year":"2012","unstructured":"Miller A.E.; Rhoades R.W.; Treatment of relapsing-remitting multiple sclerosis: current approaches and unmet needs. Curr Opin Neurol 2012,25(Suppl.),S4-S10","journal-title":"Curr Opin Neurol"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"55","DOI":"10.7224\/1537-2073.2013-006","volume":"16","author":"Filipi M.L.","year":"2014","unstructured":"Filipi M.L.; Beavin J.; Brillante R.T.; Costello K.; Hartley G.C.; Hartley K.; Namey M.; O\u2019Leary S.; Remington G.; Nurses\u2019 perspec-tive on approaches to limit flu-like symptoms during interferon therapy for multiple sclerosis. Int J MS Care 2014,16(1),55-60","journal-title":"Int J MS Care"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"165","DOI":"10.7224\/1537-2073.2018-063","volume":"22","author":"Filipi M.","year":"2020","unstructured":"Filipi M.; Jack S.; Interferons in the Treatment of Multiple Sclerosis: A Clinical Efficacy, Safety, and Tolerability Update. Int J MS Care 2020,22(4),165-172","journal-title":"Int J MS Care"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1038\/nri3787","volume":"15","author":"McNab F.","year":"2015","unstructured":"McNab F.; Mayer-Barber K.; Sher A.; Wack A.; O\u2019Garra A.; Type I interferons in infectious disease. Nat Rev Immunol 2015,15(2),87-103","journal-title":"Nat Rev Immunol"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1136\/bmj.n71","volume":"29","author":"Page M.J.","year":"2021","unstructured":"Page M.J.; McKenzie J.E.; Bossuyt P.M.; Boutron I.; Hoffmann T.C.; Mulrow C.D.; Shamseer L.; Tetzlaff J.M.; Akl E.A.; Brennan S.E.; Chou R.; Glanville J.; Grimshaw J.M.; Hr\u00f3bjartsson A.; Lalu M.M.; Li T.; Loder E.W.; Mayo-Wilson E.; McDonald S.; McGuinness L.A.; Stewart L.A.; Thomas J.; Tricco A.C.; Welch V.A.; Whiting P.; Moher D.; The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021,29,372","journal-title":"BMJ"},{"key":"ref=22","author":"Munnangi S.","year":"2021","unstructured":"Munnangi S.; Boktor S.W.;  Epidemiology of study design 2021","journal-title":"Epidemiology of study design"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1136\/bmj.39500.677199.AE","volume":"336","author":"Sch\u00fcnemann H.J.","year":"2008","unstructured":"Sch\u00fcnemann H.J.; Oxman A.D.; Brozek J.; Glasziou P.; Jaeschke R.; Vist G.E.; Williams J.W.; Kunz R.; Craig J.; Montori V.M.; Bossuyt P.; Guyatt G.H.; Grading quality of evidence and strength of recommendations for diagnostic tests and strategies. BMJ 2008,336(7653),1106-1110","journal-title":"BMJ"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","volume":"343","author":"Higgins J.P.","year":"2011","unstructured":"Higgins J.P.; Altman D.G.; G\u00f8tzsche P.C.; J\u00fcni P.; Moher D.; Oxman A.D.; Savovi\u0107, J.; Schulz, K.F.; Weeks, L.; Sterne, J.A Cochrane Bias Methods Group; Cochrane Statistical Methods Group. The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised tri-als. BMJ 2011,343,d5928","journal-title":"BMJ"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"Egger M.","year":"1997","unstructured":"Egger M.; Davey Smith G.; Schneider M.; Minder C.; Bias in meta-analysis detected by a simple, graphical test. BMJ 1997,315(7109),629-634","journal-title":"BMJ"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.2307\/2533446","volume":"50","author":"Begg C.B.","year":"1994","unstructured":"Begg C.B.; Mazumdar M.; Operating characteristics of a rank correlation test for publication bias. Biometrics 1994,50(4),1088-1101","journal-title":"Biometrics"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"5724","DOI":"10.1007\/s12035-021-02493-9","volume":"58","author":"Rodrigues P.","year":"2021","unstructured":"Rodrigues P.; Bochi G.V.; Trevisan G.; Advanced oxidative protein products role in multiple sclerosis: A systematic review and meta-analysis. Mol Neurobiol 2021,58(11),5724-5742","journal-title":"Mol Neurobiol"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","volume":"7","author":"DerSimonian R.","year":"1986","unstructured":"DerSimonian R.; Laird N.; Meta-analysis in clinical trials. Control Clin Trials 1986,7(3),177-188","journal-title":"Control Clin Trials"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1212\/01.wnl.0000237641.33768.8d","volume":"67","author":"Kappos L.","year":"2006","unstructured":"Kappos L.; Polman C.H.; Freedman M.S.; Edan G.; Hartung H.P.; Miller D.H.; Montalban X.; Barkhof F.; Bauer L.; Jakobs P.; Pohl C.; Sandbrink R.; Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology 2006,67(7),1242-1249","journal-title":"Neurology"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1177\/1352458509106937","volume":"15","author":"Montalban X.","year":"2009","unstructured":"Montalban X.; Sastre-Garriga J.; Tintor\u00e9 M.; Brieva L.; Aymerich F.X.; R\u00edo J.; Porcel J.; Borr\u00e0s C.; Nos C.; Rovira A.; A single-center, randomized, double-blind, placebo-controlled study of interferon beta-1b on primary progressive and transitional multiple sclero-sis. Mult Scler 2009,15(10),1195-1205","journal-title":"Mult Scler"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1177\/147323000503300306","volume":"33","author":"Wroe S.J.","year":"2005","unstructured":"Wroe S.J.; Effects of dose titration on tolerability and efficacy of interferon beta-1b in people with multiple sclerosis. J Int Med Res 2005,33(3),309-318","journal-title":"J Int Med Res"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/S1474-4422(14)70068-7","volume":"13","author":"Calabresi P.A.","year":"2014","unstructured":"Calabresi P.A.; Kieseier B.C.; Arnold D.L.; Balcer L.J.; Boyko A.; Pelletier J.; Liu S.; Zhu Y.; Seddighzadeh A.; Hung S.; Deykin A.; Pegylated interferon \u03b2-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study. Lancet Neurol 2014,13(7),657-665","journal-title":"Lancet Neurol"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1191\/1352458505ms1126oa","volume":"11","author":"Freedman M.S.","year":"2005","unstructured":"Freedman M.S.; Francis G.S.; Sanders E.A.C.M.; Rice G.P.A.; O\u2019Connor P.; Comi G.; Duquette P.; Metz L.; Murray T.J.; Bouchard J-P.; Abramsky O.; Pelletier J.; O\u2019Brien F.; Randomized study of once-weekly interferon \u03b2-1la therapy in relapsing multiple sclerosis: three-year data from the OWIMS study. Mult Scler 2005,11(1),41-45","journal-title":"Mult Scler"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1111\/j.1468-1331.2005.01083.x","volume":"12","author":"Gold R.","year":"2005","unstructured":"Gold R.; Rieckmann P.; Chang P.; Abdalla J.; The long-term safety and tolerability of high-dose interferon \u03b2-1a in relapsing-remitting multiple sclerosis: 4-year data from the PRISMS study. Eur J Neurol 2005,12(8),649-656","journal-title":"Eur J Neurol"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1016\/S0140-6736(11)61649-8","volume":"378","author":"Kappos L.","year":"2011","unstructured":"Kappos L.; Li D.; Calabresi P.A.; O\u2019Connor P.; Bar-Or A.; Barkhof F.; Yin M.; Leppert D.; Glanzman R.; Tinbergen J.; Hauser S.L.; Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial. Lancet 2011,378(9805),1779-1787","journal-title":"Lancet"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/S1474-4422(11)70262-9","volume":"11","author":"Comi G.","year":"2012","unstructured":"Comi G.; De Stefano N.; Freedman M.S.; Barkhof F.; Polman C.H.; Uitdehaag B.M.; Casset-Semanaz F.; Hennessy B.; Moraga M.S.; Rocak S.; Stubinski B.; Kappos L.; Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clin-ical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial. Lancet Neurol 2012,11(1),33-41","journal-title":"Lancet Neurol"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.jns.2011.08.013","volume":"312","author":"De Stefano N.","year":"2012","unstructured":"De Stefano N.; Sormani M.P.; Stubinski B.; Blevins G.; Drulovic J.S.; Issard D.; Shotekov P.; Gasperini C.; Efficacy and safety of subcutaneous interferon \u03b2-1a in relapsing-remitting multiple sclerosis: further outcomes from the IMPROVE study. J Neurol Sci 2012,312(1-2),97-101","journal-title":"J Neurol Sci"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"e00696","DOI":"10.1002\/brb3.696","volume":"7","author":"Madsen C.","year":"2017","unstructured":"Madsen C.; The innovative development in interferon beta treatments of relapsing-remitting multiple sclerosis. Brain Behav 2017,7(6),e00696","journal-title":"Brain Behav"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/1129-2377-15-21","volume":"15","author":"Bischof A.","year":"2014","unstructured":"Bischof A.; Sprenger T.; Interferon beta-associated recurrence of painful trigeminal neuropathy attributed to a multiple sclerosis plaque. J Headache Pain 2014,15(1),21","journal-title":"J Headache Pain"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"1716","DOI":"10.1111\/1471-0528.15199","volume":"125","author":"Hariton E.","year":"2018","unstructured":"Hariton E.; Locascio J.J.; Randomised controlled trials - the gold standard for effectiveness research: Study design: randomised controlled trials. BJOG 2018,125(13),1716","journal-title":"BJOG"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.msard.2013.07.001","volume":"3","author":"Freedman M.S.","year":"2014","unstructured":"Freedman M.S.; Comi G.; De Stefano N.; Barkhof F.; Polman C.H.; Uitdehaag B.M.J.; Lehr L.; Stubinski B.; Kappos L.; Moving to-ward earlier treatment of multiple sclerosis: Findings from a decade of clinical trials and implications for clinical practice. Mult Scler Relat Disord 2014,3(2),147-155","journal-title":"Mult Scler Relat Disord"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"175","DOI":"10.2147\/JPR.S79618","volume":"8","author":"Horn-Hofmann C.","year":"2015","unstructured":"Horn-Hofmann C.; B\u00fcscher P.; Lautenbacher S.; Wolstein J.; The effect of nonrecurring alcohol administration on pain perception in humans: a systematic review. J Pain Res 2015,8,175-187","journal-title":"J Pain Res"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"112734","DOI":"10.1016\/j.socscimed.2019.112734","volume":"246","author":"Dassieu L.","year":"2020","unstructured":"Dassieu L.; Kabor\u00e9 J-L.; Choini\u00e8re M.; Arruda N.; Roy \u00c9.; Painful lives: Chronic pain experience among people who use illicit drugs in Montreal (Canada). Soc Sci Med 2020,246,112734","journal-title":"Soc Sci Med"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1016\/S0140-6736(16)30959-X","volume":"389","author":"Brownlee W.J.","year":"2017","unstructured":"Brownlee W.J.; Hardy T.A.; Fazekas F.; Miller D.H.; Diagnosis of multiple sclerosis: progress and challenges. Lancet 2017,389(10076),1336-1346","journal-title":"Lancet"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1002\/ana.20703","volume":"58","author":"Polman C.H.","year":"2005","unstructured":"Polman C.H.; Reingold S.C.; Edan G.; Filippi M.; Hartung H.P.; Kappos L.; Lublin F.D.; Metz L.M.; McFarland H.F.; O\u2019Connor P.W.; Sandberg-Wollheim M.; Thompson A.J.; Weinshenker B.G.; Wolinsky J.S.; Diagnostic criteria for multiple sclerosis: 2005 revi-sions to the \u201cMcDonald Criteria\u201d. Ann Neurol 2005,58(6),840-846","journal-title":"Ann Neurol"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1111\/j.1749-6632.1965.tb20235.x","volume":"122","author":"Schumacher G.A.","year":"1965","unstructured":"Schumacher G.A.; Beebe G.; Kibler R.F.; Kurland L.T.; Kurtzke J.F.; McDowell F.; Nagler B.; Sibley W.A.; Tourtellotte W.W.; Willmon T.L.; Problems of experimental trials of therapy in multiple sclerosis: report by the panel on the evaluation of experimental trials of therapy in multiple sclerosis. Ann N Y Acad Sci 1965,122(1),552-568","journal-title":"Ann N Y Acad Sci"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1002\/ana.410130302","volume":"13","author":"Poser C.M.","year":"1983","unstructured":"Poser C.M.; Paty D.W.; Scheinberg L.; McDonald W.I.; Davis F.A.; Ebers G.C.; Johnson K.P.; Sibley W.A.; Silberberg D.H.; Tourtel-lotte W.W.; New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983,13(3),227-231","journal-title":"Ann Neurol"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1080\/1744666X.2018.1426462","volume":"14","author":"Zettl U.K.","year":"2018","unstructured":"Zettl U.K.; Hecker M.; Aktas O.; Wagner T.; Rommer P.S.; Interferon \u03b2-1a and \u03b2-1b for patients with multiple sclerosis: updates to current knowledge. Expert Rev Clin Immunol 2018,14(2),137-153","journal-title":"Expert Rev Clin Immunol"},{"key":"ref=49","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1590\/0004-282x20160185","volume":"75","author":"Comini-Frota E.R.","year":"2017","unstructured":"Comini-Frota E.R.; Vasconcelos C.C.F.; Mendes M.F.; Guideline for multiple sclerosis treatment in Brazil: Consensus from the Neuro-immunology Scientific Department of the Brazilian Academy of Neurology. Neuro-Psiquiatr 2017,75,57-65","journal-title":"Neuro-Psiquiatr"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/0304-3959(83)90088-X","volume":"16","author":"Carlsson A.M.","year":"1983","unstructured":"Carlsson A.M.; Assessment of chronic pain. I. Aspects of the reliability and validity of the visual analogue scale. Pain 1983,16(1),87-101","journal-title":"Pain"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1136\/bmj.39057.406644.68","volume":"334","author":"Fletcher J.","year":"2007","unstructured":"Fletcher J.; What is heterogeneity and is it important? BMJ 2007,334(7584),94-96","journal-title":"BMJ"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s12883-017-0831-4","volume":"17","author":"Sabid\u00f3-Espin M.","year":"2017","unstructured":"Sabid\u00f3-Espin M.; Munschauer R.; Reasons for discontinuation of subcutaneous interferon \u03b2-1a three times a week among patients with multiple sclerosis: a real-world cohort study. BMC Neurol 2017,17(1),57","journal-title":"BMC Neurol"}],"container-title":["Current Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1570159X19666211101142115","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/197528\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1570159X19666211101142115","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T11:17:08Z","timestamp":1747307828000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/197528\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":52,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1570159x19666211101142115","relation":{},"ISSN":["1570-159X"],"issn-type":[{"value":"1570-159X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2021-09-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-10-06","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-10-28","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-06-29","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}